M 002
Alternative Names: AAV-S1S3; M-002Latest Information Update: 18 Jul 2025
At a glance
- Originator M6P Therapeutics
- Class 3-ring heterocyclic compounds; Amides; Gene therapies; Small molecules
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Metabolic bone diseases
Most Recent Events
- 18 Jul 2025 M 002 is still in preclinical development in Metabolic bone diseases in USA (Parenteral) (M6P therapeutics pipeline, July 2025)
- 18 Jul 2025 M6P Therapeutics plans to file IND in Metabolic bone disorders by third quarter of 2026 (M6P Therapeutics pipeline, July 2025)
- 18 Jul 2025 Pharmacodynamics data from a preclinical studies in Mucolipidosis type II released by M6P Therapeutics